Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Zomagen Biosciences
London, United Kingdomzomagen.com ↗
- Ownership
- Private
- Employees
- ~10
- Development stage
- Other
01
Overview
VTX3232, their CNS-penetrant NLRP3 inhibitor, completed a Phase 2a trial in early-stage Parkinson’s disease, showing positive safety and biomarker results, with significant reductions in NLRP3-related biomarkers in CSF and plasma.
- Therapeutic areas
- NeurologyEndocrinologyCardiovascular
- Modalities
- Small moleculeSynthetic peptide
- Industry
- Biotech
02
Partnerships
Ventyx Biosciences (clinical data sharing for VTX3232)
Beyond the preview
Go deeper on Zomagen Biosciences.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Zomagen Biosciences.